MIMS Hong Kong - Drug Information, Disease, News
開發者：MIMS PTE. LTD.
此 App 只在 iOS 裝置的 App Store 提供。
For over 50 years, MIMS has provided trusted clinical information for over 2 million healthcare professionals in Asia. Designed for busy individuals on the go, the MIMS app is a one-stop medical resource to support clinical decisions at the point of care.
The most trusted drug and medical reference tool for doctors in Asia.
The MIMS Mobile app for IOS™ is available for free.
For more information, visit www.mims.com/mobile-app
Key features available in our app:
• Drug Information
Search for drug dosing information or specific drug interactions, and find the answers you need in seconds with our concise and comprehensive drug database.
• Disease & Condition Management Guidelines
Review a complete disease management guide and be assured of reliable content fully substantiated by validated references and internationally recognised research, to enable you to make better-informed prescribing decisions.
• Medical News & CME Updates
Read the latest news available across various specialties in Asia through our renowned publications (Medical Tribune, JPOG, Oncology Tribune, etc), and keep your knowledge and skills current with changes in medicine.
• Clinical Tools
Access 29 clinical calculators and scoring tools to facilitate effective clinical decision-making and support your practice.
Watch insightful video interviews focusing on treatment options, disease management and latest updates by experts from various specialties, and upgrade your medical knowledge.
If you have any feedback for MIMS mobile app, you can send them to bit.ly/mimsiosHK
The MIMS app is regularly updated with improved performance and features to serve our healthcare communities better.
The latest MIMS app (version 1.8) includes improvements for speed and reliability, allowing access to our medical work tools at greater ease.
Updated and interesting news articles on HK's healthcare market
I like reading the articles on the app. Keep me up to date of the healthcare news in Hong Kong.